Chad Pecot
Founder & Chief Scientific Officer EnFuego Therapeutics
Seminars
Wednesday 9th September 2026
Next Generation RNAi Therapeutics for Mutant Selective Oncogene Targeting & Dual Target Engagement
9:30 am
- Covering the development of an EGFR-directed RNAi delivery platform
- Discussion on how next generation oligonucleotide chemistries can be utilized for highly specific KRAS mutation selective inhibitors
- Exploration of how newer RNA designs can be used to co-target key combinatorial strategies to enhance efficacy in KRAS mutant cancers
